Pharsight

Drugs that contain Tacrolimus

1. Envarsus Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11077096 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US9161907 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US10548880 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(6 months from now)

US9757362 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US8617599 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US8623410 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US9763920 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(6 months from now)

US8591946 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US7994214 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(6 months from now)

US8889186 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US8623411 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US8889185 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US8586084 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US8486993 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(6 months from now)

US11419823 VELOXIS PHARMS INC Stabilized tacrolimus composition
May, 2028

(4 years from now)

US11123331 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients
May, 2028

(4 years from now)

US11110081 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients
May, 2028

(4 years from now)

US10166190 VELOXIS PHARMS INC Stabilized tacrolimus composition
May, 2028

(4 years from now)

US10864199 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients
May, 2028

(4 years from now)

US9549918 VELOXIS PHARMS INC Stabilized tacrolimus composition
May, 2028

(4 years from now)

US8664239 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients
Aug, 2028

(4 years from now)

US8685998 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jul 10, 2022

Market Authorisation Date: 10 July, 2015

Treatment: Prophylaxis of organ rejection; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection in de novo transplant patient

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ENVARSUS XR before it's drug patent expiration?
More Information on Dosage

ENVARSUS XR family patents

Family Patents